KRT8 and colonic neoplasm: The inhibition of ALBU and HNF4 expression, as well as the observed morphological changes associated with the modulation of Vimentin and CK8/18, can be ascribed to TGFβ1 activity [9, 31, 32], which is known to be carried by EVs, including those released by colon cancer cells [25, 33, 34].